ORKAMBI

Product Overview

About ORKAMBI

ORKAMBI is a prescription medication containing the active ingredients IVACAFTOR and LUMACAFTOR. It is used to treat cystic fibrosis (CF) in patients aged 2 years and older who have two copies of the F508del mutation in the CFTR gene or who have one copy of the F508del mutation in the CFTR gene and one copy of the G551D mutation in the CFTR gene.

Key Benefits & Uses

• Treats cystic fibrosis in patients with two copies of the F508del mutation in the CFTR gene.
• Treats cystic fibrosis in patients with one copy of the F508del mutation in the CFTR gene and one copy of the G551D mutation in the CFTR gene.
• Improves lung function and reduces the frequency of pulmonary exacerbations in patients with cystic fibrosis.

Active Ingredient & Action

ORKAMBI works by increasing the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which helps to regulate the movement of salt and water in and out of cells. IVACAFTOR and LUMACAFTOR, the active ingredients in ORKAMBI, are dual combination therapy that helps to restore the function of the CFTR protein, leading to improved lung function and reduced frequency of pulmonary exacerbations.

Important Notes

ORKAMBI is available in tablet form and should be taken orally once daily. It is essential to follow the recommended dosage and administration instructions provided by your healthcare provider. ORKAMBI may interact with other medications, including warfarin, and may cause side effects such as diarrhea, headache, and upper respiratory tract infection. Patients with a history of liver disease should be closely monitored while taking ORKAMBI.